Form 4: Sight Sciences Director Tamara Fountain Receives $130,000 RSU Grant as Part of Compensation Program

Sight Sciences, Inc. Director Tamara Fountain, M.D., was granted 30,952 restricted stock units (RSUs) valued at approximately $130,000 as part of the company's Non-Employee Director Compensation Program.

Summary

• Tamara Fountain, M.D., a Director at Sight Sciences, Inc. (SGHT), acquired 30,952 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• This grant was made under the Issuer's Non-Employee Director Compensation Program.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The number of RSUs granted is equal to approximately $130,000, determined by the closing price on the grant date.
• The RSUs are scheduled to vest on the earlier of June 5, 2026, and the date of the Issuer's 2026 annual meeting of stockholders.
• Vesting is contingent upon Ms. Fountain's continued service as a director on the Company's board through the vesting date.
• Following this transaction, Ms. Fountain beneficially owns 81,389 shares, which includes 44,444 shares of Common Stock, 30,952 newly granted RSUs, and 5,993 RSUs granted on January 8, 2023, all subject to vesting.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard, expected compensation event for a director, aligning their interests with the company's long-term performance. It does not indicate any negative operational or financial news.

Positives

• The RSU grant is part of a standard non-employee director compensation program, indicating a structured approach to executive remuneration.
• The grant aligns the director's interests with long-term shareholder value through equity-based compensation that vests over time.

Negatives

• The RSU grant, while standard compensation, represents potential future dilution for existing shareholders upon vesting.

Risks

• The vesting of the RSUs is subject to the Reporting Person's continued service as a director, meaning the shares are not guaranteed if service ceases before the vesting date.

Future Outlook

The newly granted RSUs are expected to vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, provided the director continues her service.

Industry Context

This Form 4 filing reflects a routine compensation event for a director in a publicly traded company within the medical technology or healthcare sector, where equity-based compensation is a common practice to align director incentives with company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of non-employee director compensation is a standard practice across various industries, including medical technology, aligning director interests with long-term shareholder value.
• The value of the grant ($130,000) and the number of units (30,952) are within typical ranges for director compensation at companies of similar market capitalization and stage of development, though specific benchmarks would require comparison to peer group proxy statements (e.g., Alcon, Bausch + Lomb, Glaukos, Ivantis, etc.).
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is also a common structure for such equity awards.

Corporate Governance

Related Party Transactions

• The RSU grant to Tamara Fountain, a Director of Sight Sciences, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant represents potential future dilution upon vesting, but it also aims to align the director's interests with shareholder value creation.
• Directors: Tamara Fountain benefits directly from the equity compensation, which incentivizes her continued service and performance.

Next Steps

• The 30,952 RSUs are expected to vest on the earlier of June 5, 2026, or the date of Sight Sciences' 2026 annual meeting of stockholders, subject to Tamara Fountain's continued service as a director.

Key Dates

Keywords

Sight Sciences, SGHT, Restricted Stock Units, RSU grant, Director compensation, SEC Form 4, Insider transaction, Equity compensation, Corporate governance